Latest Updates

Medical Management of Pulmonary Arterial Hypertension

    • Over the past two decades, considerable progress has been made in the medical management of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    • Recently the field has seen the addition of several new pulmonary vasodilator agents: a soluble guanylate cyclase stimulator (riociguat), a new endothelin receptor antagonist (macitentan) and two new oral prostanoid agents (treprostinil and selexipag).
    • Initial combination therapy for the treatment of pulmonary arterial hypertension has heralded a new era in the treatment of PAH. Patients receiving initial combination therapy with a phosphodiesterase inhibitor, tadalafil and an endothelin receptor antagonist, ambrisentan demonstrated improved progression-free survival compared with monotherapy with either tadalafil or ambrisentan.
    • For patients with inoperable or persistent chronic thromboembolic pulmonary hypertension, riociguat has emerged as an attractive alternative.

Principles of Laser Use

    • Angiolytic LASERS such as PDL and KTP lasers target oxyhemoglobin and can eradicate vascular lesions while preserving epithelium.
    • Scanners on LASERs allow the LASER beam to create shapes such as lines and semi-circles to optimize efficiency.
    • Different modes of energy delivery include ultrapulse and superpulse which allow high peak energy delivery to minimize thermal damage to surrounding tissues.

Radiation Wounds and Reconstruction

    • Fat grafting presents an emerging strategy to improve tissue quality after radiation-induced fibrosis.
    • The author is studying strategies to improve tissue-resident fat content using topical drugs.
    • Patient-reported outcomes (PROs) are an important part of research studying the efficacy of strategies against radiation-induced tissue injury.

Surgical Management of Ulcerative Colitis

    • As laparoscopic surgery becomes increasingly pervasive, both a hand-assisted and straight laparoscopic colectomy and proctectomy with ileal pouch-anal anastomosis (IPAA) have become more common, with outcomes equivalent to or even improved compared with an open approach.
    • Since the introduction of infliximab, biologic therapy has become more prevalent in the inflammatory bowel disease patient population. These medications should be held as long as possible prior to an elective operation as they have been associated with increased infectious complications following IPAA.
    • Despite biologic therapy, in the setting of an acute flare of ulcerative colitis, 50% of patients treated with intravenous steroids and an induction done of anti–tumor necrosis factor–α will still go on to have a colectomy within the year.
    • The relatively recent introduction of enhanced recovery after surgery protocols in our postoperative care has improved postoperative pain scores and decreased the length of hospital stays. These protocols use a multimodality pain management plan that avoids systemic narcotics, minimizes intravenous fluid administration, enforced early ambulation, and early enteral intake on the night of surgery. The expected length of stay following IPAA is now typically 3 days.
    • As an increasing number of immunosuppressive drugs are being introduced for the treatment of ulcerative colitis, a three-stage approach to IPAA is being more commonly employed. A three–stage approach is used for patients who require emergency surgery, are in poor medical condition due to their underlying disease, or are significantly immunosuppressed.

Surgical Management of Ulcerative Colitis

    • As laparoscopic surgery becomes increasingly pervasive, both a hand-assisted and straight laparoscopic colectomy and proctectomy with ileal pouch-anal anastomosis (IPAA) have become more common, with outcomes equivalent to or even improved compared with an open approach.
    • Since the introduction of infliximab, biologic therapy has become more prevalent in the inflammatory bowel disease patient population. These medications should be held as long as possible prior to an elective operation as they have been associated with increased infectious complications following IPAA.
    • Despite biologic therapy, in the setting of an acute flare of ulcerative colitis, 50% of patients treated with intravenous steroids and an induction done of anti–tumor necrosis factor–α will still go on to have a colectomy within the year.
    • The relatively recent introduction of enhanced recovery after surgery protocols in our postoperative care has improved postoperative pain scores and decreased the length of hospital stays. These protocols use a multimodality pain management plan that avoids systemic narcotics, minimizes intravenous fluid administration, enforced early ambulation, and early enteral intake on the night of surgery. The expected length of stay following IPAA is now typically 3 days.
    • As an increasing number of immunosuppressive drugs are being introduced for the treatment of ulcerative colitis, a three-stage approach to IPAA is being more commonly employed. A three–stage approach is used for patients who require emergency surgery, are in poor medical condition due to their underlying disease, or are significantly immunosuppressed.

New Techniques in Hemorrhage Control

    • Use of angioembolization for diagnosis and treatment of hemorrhage; improvement in angioembolization devices and technology
    • Success of thoracic endovascular aortic repair (TEVAR) using endovascular stent grafts to improve morbidity and mortality among patients who survive blunt thoracic aortic injury (BTAI) has led to inquiries into use of stent grafts at other anatomic sites
    • Use of resuscitative endovascular balloon occlusion of the aorta (REBOA) may be an important adjunct in the control of life-threatening hemorrhage; various physiologic parameters have been shown to improve with REBOA
    • Minimally invasive techniques for hemorrhage control: intra-abdominal foam and tourniquets

New Techniques in Hemorrhage Control

    • Use of angioembolization for diagnosis and treatment of hemorrhage; improvement in angioembolization devices and technology
    • Success of thoracic endovascular aortic repair (TEVAR) using endovascular stent grafts to improve morbidity and mortality among patients who survive blunt thoracic aortic injury (BTAI) has led to inquiries into use of stent grafts at other anatomic sites
    • Use of resuscitative endovascular balloon occlusion of the aorta (REBOA) may be an important adjunct in the control of life-threatening hemorrhage; various physiologic parameters have been shown to improve with REBOA
    • Minimally invasive techniques for hemorrhage control: intra-abdominal foam and tourniquets

New Techniques in Hemorrhage Control

    • Use of angioembolization for diagnosis and treatment of hemorrhage; improvement in angioembolization devices and technology
    • Success of thoracic endovascular aortic repair (TEVAR) using endovascular stent grafts to improve morbidity and mortality among patients who survive blunt thoracic aortic injury (BTAI) has led to inquiries into use of stent grafts at other anatomic sites
    • Use of resuscitative endovascular balloon occlusion of the aorta (REBOA) may be an important adjunct in the control of life-threatening hemorrhage; various physiologic parameters have been shown to improve with REBOA
    • Minimally invasive techniques for hemorrhage control: intra-abdominal foam and tourniquets
« Previous | Next »
Updates per yearSpecialty updatesNumber of sections